Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication

Bis-tetraazamacrocycles such as the bicyclam AMD3100 (1) are a class of potent and selective anti-HIV-1 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the coreceptor for entry of X4 viruses. By sequential replacement and/or deletion of the amino groups within the a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2010-02, Vol.53 (3), p.1250-1260
Hauptverfasser: Bridger, Gary J, Skerlj, Renato T, Hernandez-Abad, Pedro E, Bogucki, David E, Wang, Zhongren, Zhou, Yuanxi, Nan, Susan, Boehringer, Eva M, Wilson, Trevor, Crawford, Jason, Metz, Markus, Hatse, Sigrid, Princen, Katrien, De Clercq, Erik, Schols, Dominique
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1260
container_issue 3
container_start_page 1250
container_title Journal of medicinal chemistry
container_volume 53
creator Bridger, Gary J
Skerlj, Renato T
Hernandez-Abad, Pedro E
Bogucki, David E
Wang, Zhongren
Zhou, Yuanxi
Nan, Susan
Boehringer, Eva M
Wilson, Trevor
Crawford, Jason
Metz, Markus
Hatse, Sigrid
Princen, Katrien
De Clercq, Erik
Schols, Dominique
description Bis-tetraazamacrocycles such as the bicyclam AMD3100 (1) are a class of potent and selective anti-HIV-1 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the coreceptor for entry of X4 viruses. By sequential replacement and/or deletion of the amino groups within the azamacrocyclic ring systems, we have determined the minimum structural features required for potent antiviral activity in this class of compounds. All eight amino groups are not required for activity, the critical amino groups on a per ring basis are nonidentical, and the overall charge at physiological pH can be reduced without compromising potency. This approach led to the identification of several single ring azamacrocyclic analogues such as AMD3465 (3d), 36, and 40, which exhibit EC50’s against the cytopathic effects of HIV-1 of 9.0, 1.0, and 4.0 nM, respectively, antiviral potencies that are comparable to 1 (EC50 against HIV-1 of 4.0 nM). More importantly, however, the key structural elements of 1 required for antiviral activity may facilitate the design of nonmacrocyclic CXCR4 antagonists suitable for HIV treatment via oral administration.
doi_str_mv 10.1021/jm901530b
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733701576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733701576</sourcerecordid><originalsourceid>FETCH-LOGICAL-a344t-eedb18a28e72156cf43cbc545e87ab5074d45ad35f6013569fb1dff93afa7933</originalsourceid><addsrcrecordid>eNptkc1uEzEUhS0EoqGw4AWQNwi6GPDf_IRdNAIaqRKoiVB3ozseO3GYsQfbgxSegDWPx5InqZuGVkKsrnz93XPP1UHoOSVvKGH07W6YE5pz0j5AM5ozkomKiIdoRghjGSsYP0FPQtgRQjhl_DE6YYQIXvBqhn6v9jZuVTABg-3wKvpJxsmrPz9_LWQ0303c40vVQzTOhq0ZA3YaL37AANI7uZe9kbjOrrIa11s1uK_GqsRLNUbnscALG2HjrAkxvEsP6N1mUgHXLvWNNXaDAa9S6dW_opeHT6_wZxeVjXhpt6Y1SfXgYJ3Vqu_x2rsxsa-vxBk-X37JaNo9pumD3afokYY-qGfHeorWH96v6_Ps4tPHZb24yIALETOlupZWwCpVMpoXUgsuW5mLXFUltDkpRSdy6HiuC0J5Xsx1Szut5xw0lHPOT9GrW9nRu2_puNgMJsjkDqxyU2hKzsuUTlkk8uyWTFeG4JVuRm8G8PuGkuYmyOYuyMS-OKpO7aC6O_Jvcgl4eQQgSOi1BytNuOeYyAXl9J4DGZqdm3wKIfxn4TUwwrVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733701576</pqid></control><display><type>article</type><title>Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication</title><source>ACS Publications</source><source>MEDLINE</source><creator>Bridger, Gary J ; Skerlj, Renato T ; Hernandez-Abad, Pedro E ; Bogucki, David E ; Wang, Zhongren ; Zhou, Yuanxi ; Nan, Susan ; Boehringer, Eva M ; Wilson, Trevor ; Crawford, Jason ; Metz, Markus ; Hatse, Sigrid ; Princen, Katrien ; De Clercq, Erik ; Schols, Dominique</creator><creatorcontrib>Bridger, Gary J ; Skerlj, Renato T ; Hernandez-Abad, Pedro E ; Bogucki, David E ; Wang, Zhongren ; Zhou, Yuanxi ; Nan, Susan ; Boehringer, Eva M ; Wilson, Trevor ; Crawford, Jason ; Metz, Markus ; Hatse, Sigrid ; Princen, Katrien ; De Clercq, Erik ; Schols, Dominique</creatorcontrib><description>Bis-tetraazamacrocycles such as the bicyclam AMD3100 (1) are a class of potent and selective anti-HIV-1 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the coreceptor for entry of X4 viruses. By sequential replacement and/or deletion of the amino groups within the azamacrocyclic ring systems, we have determined the minimum structural features required for potent antiviral activity in this class of compounds. All eight amino groups are not required for activity, the critical amino groups on a per ring basis are nonidentical, and the overall charge at physiological pH can be reduced without compromising potency. This approach led to the identification of several single ring azamacrocyclic analogues such as AMD3465 (3d), 36, and 40, which exhibit EC50’s against the cytopathic effects of HIV-1 of 9.0, 1.0, and 4.0 nM, respectively, antiviral potencies that are comparable to 1 (EC50 against HIV-1 of 4.0 nM). More importantly, however, the key structural elements of 1 required for antiviral activity may facilitate the design of nonmacrocyclic CXCR4 antagonists suitable for HIV treatment via oral administration.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm901530b</identifier><identifier>PMID: 20043638</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Columbus, OH: American Chemical Society</publisher><subject>Anti-HIV Agents - chemical synthesis ; Anti-HIV Agents - chemistry ; Anti-HIV Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Heterocyclic Compounds - chemical synthesis ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; HIV Infections - drug therapy ; HIV-1 - drug effects ; Humans ; Immunomodulators ; Medical sciences ; Models, Chemical ; Molecular Structure ; Pharmacology. Drug treatments ; Pyridines - chemistry ; Pyridines - pharmacology ; Receptors, CXCR4 - antagonists &amp; inhibitors ; Structure-Activity Relationship ; T-Lymphocytes ; Virus Replication - drug effects</subject><ispartof>Journal of medicinal chemistry, 2010-02, Vol.53 (3), p.1250-1260</ispartof><rights>Copyright © 2009 American Chemical Society</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a344t-eedb18a28e72156cf43cbc545e87ab5074d45ad35f6013569fb1dff93afa7933</citedby><cites>FETCH-LOGICAL-a344t-eedb18a28e72156cf43cbc545e87ab5074d45ad35f6013569fb1dff93afa7933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm901530b$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm901530b$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22454131$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20043638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bridger, Gary J</creatorcontrib><creatorcontrib>Skerlj, Renato T</creatorcontrib><creatorcontrib>Hernandez-Abad, Pedro E</creatorcontrib><creatorcontrib>Bogucki, David E</creatorcontrib><creatorcontrib>Wang, Zhongren</creatorcontrib><creatorcontrib>Zhou, Yuanxi</creatorcontrib><creatorcontrib>Nan, Susan</creatorcontrib><creatorcontrib>Boehringer, Eva M</creatorcontrib><creatorcontrib>Wilson, Trevor</creatorcontrib><creatorcontrib>Crawford, Jason</creatorcontrib><creatorcontrib>Metz, Markus</creatorcontrib><creatorcontrib>Hatse, Sigrid</creatorcontrib><creatorcontrib>Princen, Katrien</creatorcontrib><creatorcontrib>De Clercq, Erik</creatorcontrib><creatorcontrib>Schols, Dominique</creatorcontrib><title>Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Bis-tetraazamacrocycles such as the bicyclam AMD3100 (1) are a class of potent and selective anti-HIV-1 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the coreceptor for entry of X4 viruses. By sequential replacement and/or deletion of the amino groups within the azamacrocyclic ring systems, we have determined the minimum structural features required for potent antiviral activity in this class of compounds. All eight amino groups are not required for activity, the critical amino groups on a per ring basis are nonidentical, and the overall charge at physiological pH can be reduced without compromising potency. This approach led to the identification of several single ring azamacrocyclic analogues such as AMD3465 (3d), 36, and 40, which exhibit EC50’s against the cytopathic effects of HIV-1 of 9.0, 1.0, and 4.0 nM, respectively, antiviral potencies that are comparable to 1 (EC50 against HIV-1 of 4.0 nM). More importantly, however, the key structural elements of 1 required for antiviral activity may facilitate the design of nonmacrocyclic CXCR4 antagonists suitable for HIV treatment via oral administration.</description><subject>Anti-HIV Agents - chemical synthesis</subject><subject>Anti-HIV Agents - chemistry</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Heterocyclic Compounds - chemical synthesis</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1 - drug effects</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Medical sciences</subject><subject>Models, Chemical</subject><subject>Molecular Structure</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridines - chemistry</subject><subject>Pyridines - pharmacology</subject><subject>Receptors, CXCR4 - antagonists &amp; inhibitors</subject><subject>Structure-Activity Relationship</subject><subject>T-Lymphocytes</subject><subject>Virus Replication - drug effects</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc1uEzEUhS0EoqGw4AWQNwi6GPDf_IRdNAIaqRKoiVB3ozseO3GYsQfbgxSegDWPx5InqZuGVkKsrnz93XPP1UHoOSVvKGH07W6YE5pz0j5AM5ozkomKiIdoRghjGSsYP0FPQtgRQjhl_DE6YYQIXvBqhn6v9jZuVTABg-3wKvpJxsmrPz9_LWQ0303c40vVQzTOhq0ZA3YaL37AANI7uZe9kbjOrrIa11s1uK_GqsRLNUbnscALG2HjrAkxvEsP6N1mUgHXLvWNNXaDAa9S6dW_opeHT6_wZxeVjXhpt6Y1SfXgYJ3Vqu_x2rsxsa-vxBk-X37JaNo9pumD3afokYY-qGfHeorWH96v6_Ps4tPHZb24yIALETOlupZWwCpVMpoXUgsuW5mLXFUltDkpRSdy6HiuC0J5Xsx1Szut5xw0lHPOT9GrW9nRu2_puNgMJsjkDqxyU2hKzsuUTlkk8uyWTFeG4JVuRm8G8PuGkuYmyOYuyMS-OKpO7aC6O_Jvcgl4eQQgSOi1BytNuOeYyAXl9J4DGZqdm3wKIfxn4TUwwrVQ</recordid><startdate>20100211</startdate><enddate>20100211</enddate><creator>Bridger, Gary J</creator><creator>Skerlj, Renato T</creator><creator>Hernandez-Abad, Pedro E</creator><creator>Bogucki, David E</creator><creator>Wang, Zhongren</creator><creator>Zhou, Yuanxi</creator><creator>Nan, Susan</creator><creator>Boehringer, Eva M</creator><creator>Wilson, Trevor</creator><creator>Crawford, Jason</creator><creator>Metz, Markus</creator><creator>Hatse, Sigrid</creator><creator>Princen, Katrien</creator><creator>De Clercq, Erik</creator><creator>Schols, Dominique</creator><general>American Chemical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100211</creationdate><title>Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication</title><author>Bridger, Gary J ; Skerlj, Renato T ; Hernandez-Abad, Pedro E ; Bogucki, David E ; Wang, Zhongren ; Zhou, Yuanxi ; Nan, Susan ; Boehringer, Eva M ; Wilson, Trevor ; Crawford, Jason ; Metz, Markus ; Hatse, Sigrid ; Princen, Katrien ; De Clercq, Erik ; Schols, Dominique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a344t-eedb18a28e72156cf43cbc545e87ab5074d45ad35f6013569fb1dff93afa7933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anti-HIV Agents - chemical synthesis</topic><topic>Anti-HIV Agents - chemistry</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Heterocyclic Compounds - chemical synthesis</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1 - drug effects</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Medical sciences</topic><topic>Models, Chemical</topic><topic>Molecular Structure</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridines - chemistry</topic><topic>Pyridines - pharmacology</topic><topic>Receptors, CXCR4 - antagonists &amp; inhibitors</topic><topic>Structure-Activity Relationship</topic><topic>T-Lymphocytes</topic><topic>Virus Replication - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bridger, Gary J</creatorcontrib><creatorcontrib>Skerlj, Renato T</creatorcontrib><creatorcontrib>Hernandez-Abad, Pedro E</creatorcontrib><creatorcontrib>Bogucki, David E</creatorcontrib><creatorcontrib>Wang, Zhongren</creatorcontrib><creatorcontrib>Zhou, Yuanxi</creatorcontrib><creatorcontrib>Nan, Susan</creatorcontrib><creatorcontrib>Boehringer, Eva M</creatorcontrib><creatorcontrib>Wilson, Trevor</creatorcontrib><creatorcontrib>Crawford, Jason</creatorcontrib><creatorcontrib>Metz, Markus</creatorcontrib><creatorcontrib>Hatse, Sigrid</creatorcontrib><creatorcontrib>Princen, Katrien</creatorcontrib><creatorcontrib>De Clercq, Erik</creatorcontrib><creatorcontrib>Schols, Dominique</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bridger, Gary J</au><au>Skerlj, Renato T</au><au>Hernandez-Abad, Pedro E</au><au>Bogucki, David E</au><au>Wang, Zhongren</au><au>Zhou, Yuanxi</au><au>Nan, Susan</au><au>Boehringer, Eva M</au><au>Wilson, Trevor</au><au>Crawford, Jason</au><au>Metz, Markus</au><au>Hatse, Sigrid</au><au>Princen, Katrien</au><au>De Clercq, Erik</au><au>Schols, Dominique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2010-02-11</date><risdate>2010</risdate><volume>53</volume><issue>3</issue><spage>1250</spage><epage>1260</epage><pages>1250-1260</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Bis-tetraazamacrocycles such as the bicyclam AMD3100 (1) are a class of potent and selective anti-HIV-1 agents that inhibit virus replication by binding to the chemokine receptor CXCR4, the coreceptor for entry of X4 viruses. By sequential replacement and/or deletion of the amino groups within the azamacrocyclic ring systems, we have determined the minimum structural features required for potent antiviral activity in this class of compounds. All eight amino groups are not required for activity, the critical amino groups on a per ring basis are nonidentical, and the overall charge at physiological pH can be reduced without compromising potency. This approach led to the identification of several single ring azamacrocyclic analogues such as AMD3465 (3d), 36, and 40, which exhibit EC50’s against the cytopathic effects of HIV-1 of 9.0, 1.0, and 4.0 nM, respectively, antiviral potencies that are comparable to 1 (EC50 against HIV-1 of 4.0 nM). More importantly, however, the key structural elements of 1 required for antiviral activity may facilitate the design of nonmacrocyclic CXCR4 antagonists suitable for HIV treatment via oral administration.</abstract><cop>Columbus, OH</cop><pub>American Chemical Society</pub><pmid>20043638</pmid><doi>10.1021/jm901530b</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2010-02, Vol.53 (3), p.1250-1260
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_733701576
source ACS Publications; MEDLINE
subjects Anti-HIV Agents - chemical synthesis
Anti-HIV Agents - chemistry
Anti-HIV Agents - pharmacology
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Heterocyclic Compounds - chemical synthesis
Heterocyclic Compounds - chemistry
Heterocyclic Compounds - pharmacology
HIV Infections - drug therapy
HIV-1 - drug effects
Humans
Immunomodulators
Medical sciences
Models, Chemical
Molecular Structure
Pharmacology. Drug treatments
Pyridines - chemistry
Pyridines - pharmacology
Receptors, CXCR4 - antagonists & inhibitors
Structure-Activity Relationship
T-Lymphocytes
Virus Replication - drug effects
title Synthesis and Structure−Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A11%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20Structure%E2%88%92Activity%20Relationships%20of%20Azamacrocyclic%20C-X-C%20Chemokine%20Receptor%204%20Antagonists:%20Analogues%20Containing%20a%20Single%20Azamacrocyclic%20Ring%20are%20Potent%20Inhibitors%20of%20T-Cell%20Tropic%20(X4)%20HIV-1%20Replication&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Bridger,%20Gary%20J&rft.date=2010-02-11&rft.volume=53&rft.issue=3&rft.spage=1250&rft.epage=1260&rft.pages=1250-1260&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm901530b&rft_dat=%3Cproquest_cross%3E733701576%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733701576&rft_id=info:pmid/20043638&rfr_iscdi=true